Related references
Note: Only part of the references are listed.Survival of patients with metastatic HER2 positive gastroesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on frontline chemotherapy plus trastuzumab.
Justin Moser et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN gamma secretion
Bharat K. R. Chaganty et al.
CANCER LETTERS (2018)
Cancer incidence and mortality in China, 2014
Wanqing Chen et al.
CHINESE JOURNAL OF CANCER RESEARCH (2018)
Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study
Giandomenico Roviello et al.
MEDICINE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Clinical efficacy of immune checkpoint inhibitors in the treatment of unresectable advanced or recurrent gastric cancer: an evidence-based review of therapies
Kazuhiro Togasaki et al.
ONCOTARGETS AND THERAPY (2018)
Correlation between human epidermal growth factor receptor 2 expression level and efficacy of trastuzumab beyond progression in metastatic gastric cancer
Yukiya Narita et al.
ONCOLOGY LETTERS (2017)
Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study
Juliette Palle et al.
ONCOTARGET (2017)
Targeted therapies for gastric cancer: failures and hopes from clinical trials
Maria Apicella et al.
ONCOTARGET (2017)
Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study
Didier Meulendijks et al.
INVESTIGATIONAL NEW DRUGS (2016)
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
E. C. Smyth et al.
ANNALS OF ONCOLOGY (2016)
Optimal regimen of trastuzumab in combination with oxaliplatin/capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial
Jifang Gong et al.
BMC CANCER (2016)
Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study
Qian Li et al.
ONCOTARGET (2016)
Gastric cancer: current and evolving treatment landscape
Weijing Sun et al.
CHINESE JOURNAL OF CANCER (2016)
Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer
Min-Hee Ryu et al.
EUROPEAN JOURNAL OF CANCER (2015)
A multicenter, phase II study of trastuzumab plus capecitabine and oxaliplatin (XELOX) as first-line chemotherapy for HER2-positive advanced gastric cancer: Update results of efficacy and toxicity.
Jifang Gong et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Treatment of gastric cancer
Michele Orditura et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis
Koji Oba et al.
EUROPEAN JOURNAL OF CANCER (2013)
Gastric Cancer: Current Status of Diagnosis and Treatment
Tsunehiro Takahashi et al.
Cancers (2013)
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Targeting Gastric Cancer with Trastuzumab: New Clinical Practice and Innovative Developments to Overcome Resistance
Dimitrios H. Roukos
ANNALS OF SURGICAL ONCOLOGY (2010)
Why Observational Studies Should Be Among The Tools Used In Comparative Effectiveness Research
Nancy A. Dreyer et al.
HEALTH AFFAIRS (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Registries for Robust Evidence
Nancy A. Dreyer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
C. Gravalos et al.
ANNALS OF ONCOLOGY (2008)
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
H Joensuu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
